MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jcmg.2025.03.014

Медицинская библиотека · JACC. Cardiovascular imaging · 2025

Uncertain Clinical Relevance of Serial Bone Scintigraphy Findings in Treated Transthyretin Amyloid Cardiomyopathy.

Razvi Yousuf, Porcari Aldostefano, Hutt David F, Lazari Jonathan, Ioannou Adam, Patel Rishi K, Rauf Muhammad Umaid, Rezk Tamer, Hague Oliver, Filisetti Stefano, Lachmann Helen J, Wechalekar Ashutosh D, Petrie Aviva, Whelan Carol J, Venneri Lucia, Martinez-Naharro Ana, Gilbertson Janet A, Rowczenio Dorota, Moody William E, Steeds Richard, Pinney Jennifer H, Hawkins Philip N, Fontana Marianna, Gillmore Julian D

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Technetium-99m-labeled 3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) scintigraphy is a critical part of the validated nonbiopsy diagnostic algorithm for transthyretin amyloid cardiomyopathy (ATTR-CM). With the advent of novel disease-modifying therapies for ATTR-CM, there is intense interest in establishing the utility of DPD scans as an indicator of treatment response.

OBJECTIVES

The authors conducted a retrospective multimodality imaging study to determine the utility of 99mTc-DPD to track treatment response in ATTR-CM.

METHODS

ATTR-CM patients from the United Kingdom National Amyloidosis Centre who were receiving amyloid-specific disease-modifying therapy (DMT) and underwent pre- and post-treatment 99mTc-DPD/single-photon emission computed tomography-computed tomography scans were included. Myocardial percentage injected dose (PID), a proposed scintigraphic indicator of cardiac amyloid burden, was measured at baseline and follow-up. Change from baseline in this variable was compared with that of other validated biomarkers of disease severity.

RESULTS

A total of 66 patients with ATTR-CM who received DMT underwent serial 99mTc-DPD scans. At follow-up, with a median time between 99mTc-DPD scans of 27.5 months (Q1-Q3: 21.9-33.1 months), there was a mean reduction from pre-DMT myocardial PID on 99mTc-DPD scintigraphy of 1.5 ± 1.5%. No statistically significant correlation between the change in PID at follow-up and change in echocardiographic, biochemical, or cardiac magnetic resonance parameters was identified. Discordance in which there was an improvement on follow-up 99mTc-DPD scintigraphy despite disease progression was observed in 28/66 patients (42.4%).

CONCLUSIONS

Our study indicates a poor correlation between reduction in 99mTc-DPD uptake at follow-up and numerous established biomarkers of ATTR-CM treatment response. Changes in DPD uptake in ATTR-CM patients receiving DMT should be interpreted with caution.

Для цитирования: Razvi Yousuf, Porcari Aldostefano, Hutt David F, Lazari Jonathan, Ioannou Adam, Patel Rishi K, Rauf Muhammad Umaid, Rezk Tamer, Hague Oliver, Filisetti Stefano, Lachmann Helen J, Wechalekar Ashutosh D, Petrie Aviva, Whelan Carol J, Venneri Lucia, Martinez-Naharro Ana, Gilbertson Janet A, Rowczenio Dorota, Moody William E, Steeds Richard, Pinney Jennifer H, Hawkins Philip N, Fontana Marianna, Gillmore Julian D. Uncertain Clinical Relevance of Serial Bone Scintigraphy Findings in Treated Transthyretin Amyloid Cardiomyopathy.. JACC. Cardiovascular imaging. 2025. DOI: 10.1016/j.jcmg.2025.03.014.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.